Table 1 Patient demographics and baseline characteristics.
Ibrutinib plus modified RICE (n = 11) | Ibrutinib plus RVICI (n = 10) | |
|---|---|---|
Median age (range), years | 11.0 (3–17) | 8.0 (4–15) |
Age group, years, n (%) | ||
1–5 | 2 (18.2) | 2 (20.0) |
6–11 | 4 (36.4) | 6 (60.0) |
12–17 | 5 (45.5) | 2 (20.0) |
Sex, n (%) | ||
Female | 3 (27.3) | 1 (10.0) |
Male | 8 (72.7) | 9 (90.0) |
Ethnicity, n (%) | ||
Hispanic or Latino | 2 (18.2) | 0 |
Not Hispanic or Latino | 6 (54.5) | 9 (90.0) |
Unknown | 1 (9.1) | 0 |
Not reported | 2 (18.2) | 1 (10.0) |
Race, n (%) | ||
White | 9 (81.8) | 10 (100.0) |
Asian | 1 (9.1) | 0 |
Not reported | 1 (9.1) | 0 |
Time from initial diagnosis to first dose of study drug (months) | ||
Mean (SD) | 11.7 (10.94) | 10.5 (6.22) |
Median (range) | 7.0 (4–37) | 8.2 (5–25) |
Type of mature B-cell NHL at initial diagnosis, n (%) | ||
Burkitt-like lymphoma | 2 (18.2) | 1 (10.0) |
Burkitt lymphoma | 4 (36.4) | 3 (30.0) |
Burkitt leukemia | 2 (18.2) | 4 (40.0) |
Diffuse large B-cell lymphoma | 3 (27.3) | 0 |
Primary mediastinal B-cell lymphoma | 0 | 1 (10.0) |
High-grade B-cell lymphoma | 0 | 1 (10.0) |
Other | 0 | 0 |
Extra nodal sites, n (%) | ||
Central nervous system | 0 | 4 (40.0) |
Bone marrow | 3 (27.3) | 4 (40.0) |
Other | 9 (81.8) | 9 (90.0) |
Prior lines of therapy, n (%) | ||
1 | 10 (90.9) | 4 (40.0) |
>1 | 1 (9.1) | 6 (60.0) |
